Merck & Co., Inc. (NYSE:MRK) has received an upgraded price target from Citi, reflecting the pharmaceutical giant’s robust product pipeline and strengths in oncology. On October 13, 2024, Citi resumed coverage of Merck with a Neutral rating, increasing its price target to $95 from the previous $84. Analysts point to the performance of key drugs, particularly Keytruda, as central to investor interest.
Merck is widely recognized for its impactful contributions to oncology, primarily through Keytruda, the best-selling medicine globally. The company also offers treatments for diabetes and vaccines for diseases such as HPV and chickenpox. Merck’s commitment to innovation has been evident in its recent acquisition spree, which includes companies like Harpoon Therapeutics, Abceutics, EyeBio, and Modifi Biosciences. Notably, in 2025, Merck completed a $3.4 billion acquisition of SpringWorks Therapeutics.
The company is currently undergoing a leadership transition, which has added an additional layer of complexity to its operations. Despite this, analysts remain optimistic about Merck’s future. Citi’s analysis highlights the importance of Keytruda, along with emerging therapies such as Qlex and Winrevair, as pivotal in driving the company’s growth.
Merck also boasts a solid track record in dividend growth, having increased its payouts for 16 consecutive years. The company currently offers a quarterly dividend of $0.81 per share, translating to a dividend yield of 3.81% as of October 14, 2024. This consistency in returning value to shareholders enhances its appeal to income-focused investors.
While the outlook for Merck appears favorable, some analysts express that opportunities in artificial intelligence (AI) stocks could offer higher returns with less risk. For those considering alternatives, reports highlighting promising AI stocks suggest potential upsides exceeding 100x.
As the pharmaceutical landscape evolves, Merck’s strategic decisions and product developments will play a critical role in shaping its market position. Investors will be closely monitoring the company’s performance and any further updates regarding its leadership transition and product pipeline advancements.
